Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Rhythm Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 102.41 · opened flat. High/low 102.40 at 4:00 am ET, 96.72 at 11:15 am ET.
Rhythm Pharmaceuticals, Inc. has 13 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Rhythm Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the terms of the Camurus license agreement, assuming that the weekly formulation of setmelanotide is successfully developed, receives regulatory approval and is commercialized, Camurus may receive aggregate payments of up to $64.8 million upon the achievement of certain development and commercial milestones under the license agreement and royalties on future product sales.”
FILING10-K0001628280-26-012399cik 0001649904
“Our partner CGC Genetics Unilabs conducts genetic testing for ROAD.”
FILING10-K0001628280-26-012399cik 0001649904
“We have licensed our rights to setmelanotide from Ipsen, and our rights to bivamelagon from LGC.”
FILING10-K0001628280-26-012399cik 0001649904
“Under the terms of the LG Chem license agreement, we have paid LG Chem $80 million in cash and issued shares to them of our common stock with an aggregate value of $20 million.”
FILING10-K0001628280-26-012399cik 0001649904
“Pursuant to the terms of the license agreement, we obtained exclusive worldwide rights to develop LGC's proprietary compound bivamelagon.”
FILING10-K0001628280-26-012399cik 0001649904
“Our U.S. partner, Prevention Genetics, a subsidiary of Exact Sciences Corp., a Clinical Laboratory Improvement Amendments-College of American Pathologists of CLIA/CAP-certified independent laboratory, conducts the genetic testing for URO.”
FILING10-K0001628280-26-012399cik 0001649904
“In addition, as part of the program, licensed genetic counselors from PWN Health, a leading provider of professional guidance for diagnostic and genetic testing, are available to advise participating individuals.”
FILING10-K0001628280-26-012399cik 0001649904
“On July 9, 2025, we entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and BofA Securities, Inc., as the representatives of the several underwriters named in the Underwriting Agreement (collectively, the "Underwriters"), in connection with a follow-on offering, issuance and sale by us of 2,058,824 shares of the Company's common stock.”
FILING10-K0001628280-26-012399cik 0001649904
“On November 2, 2021, we entered into a Sales Agreement with Cowen and Company, LLC ("Cowen"), pursuant to which we may issue and sell shares of its common stock, having an aggregate offering price of up to $100.0 million, from time to time through an "at the market" equity offering program under which Cowen acts as sales agent (the "ATM Program").”
FILING10-K0001628280-26-012399cik 0001649904
“On June 16, 2022, we entered into the RIFA with HealthCare Royalty, for a total investment amount of up to $100 million.”
FILING10-K0001628280-26-012399cik 0001649904
“On July 9, 2025, we entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and BofA Securities, Inc., as the representatives of the several underwriters named in the Underwriting Agreement (collectively, the "Underwriters"), in connection with a follow-on offering, issuance and sale by us of 2,058,824 shares of the Company's common stock.”
FILING10-K0001628280-26-012399cik 0001649904
“We have entered into process development and manufacturing service agreements with our CMOs, PolyPeptide Group, Braine L'Alleud, or Polypeptide, Neuland Laboratories, and Astrea Monts S.A.S. (formerly Recipharm), or Astrea, for certain process development and manufacturing services for regulatory starting materials and/or raw materials in connection with the manufacture of setmelanotide.”
FILING10-K0001628280-26-012399cik 0001649904
“During the year ended December 31, 2025 , we recognized a reduction of previously recognized license revenue of $5.0 million in connection with the termination of our exclusive license agreement with RareStone.”
FILING10-K0001628280-26-012399cik 0001649904
“In April 2024, we received $147.8 million in net proceeds under the Investment Agreement, with certain affiliates of Perceptive Advisors LLC, or Perceptive, and certain other investors, relating to the issuance and sale of 150,000 shares of a new series of the Company's Convertible Preferred Stock for an aggregate purchase price of $150.0 million, or $1,000 per share - see Note 9 to our consolidated financial statements - Series A Convertible Preferred Stock for additional information.”
FILING10-K0001628280-26-012399cik 0001649904
Watchlist prices, news filtered to it, and its next report on your desk.
RYTM (Rhythm Pharmaceuticals, Inc.) has 13 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.